Postoperative Pain
Conditions
Brief summary
The aim of this study is to investigate the role of 0.5 micrograms/kg of dexmedetomidine with 0.2 % ropivacaine in erector spinae block in reducing opioid consumption for patients undergoing lumbar spine surgeries. This study will help in understanding the role of adding dexmdetomidine to ropivacaine in erector spinae block in reducing opioid consumption after lumbar spine surgeries
Detailed description
A number of adjuvants have been used with local anesthetics including dexamethasone, nalbuphine and dexmedetomidine etc with the aim of improving quality and duration of peripheral nerve blocks. Dexmedetomidine is a potent alpha-2 agonist which can prolong the duration of regional anesthesia block when used in combination with local anesthetics. Although, there is no consensus on the dose of dexmedetomidine for peripheral nerve block considering the fact that it can lower heart rate and blood pressure intraoperatively. Investigators therefore, planned this randomised controlled trial to investigate the role of 0.5 micrograms/kg of dexmedetomidine with 0.2 % ropivacaine in erector spinae block for patients undergoing lumbar spine surgeries.
Interventions
OTHERESPB (regional Block)
ESPB is regional block in which we will use 0.2 % ropivacaine and dexmedetomidine
0.2 % ropivacaine and dexmedetomidine
Sponsors
Security Forces Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Procedure will be done after patient will undergo GA for surgery. Medications will be prepared by anesthetist not involved in the study. The nurse/doctor who will assess the outcome will not know the group allocation
Intervention model description
2 groups, one with block and other with no block
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patients aged between 18 and 70 years, scheduled to undergo lumbar spine surgeries with an ASA score of 1 to 3 will be included in the study
Exclusion criteria
* Patients who refused enrollment or later requested removal for the study, those who are unable to give informed consent and patients with either contraindications for regional anesthesia, known allergy to local anesthetics or dexmedetomidine, bleeding diathesis, use of anticoagulants or corticosteroids, inability to operate patient controlled analgesia (PCA) system, psychiatric disorders or use of psychiatric medications will not be included in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 24 hours opioid consumption | 24 hours | opioid consumption in mg during first 4 hours postoperatively |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| pain score | 24 hours | pain score in Numerical rating score during first 24 hours postoperatively |
| Occurrence of postoperative nausea and vomiting (PONV) | 24 hours | Occurrence of postoperative nausea and vomiting (PONV) during first 24 hours |
| Occurrence of drowsiness | 24 hours | Occurrence of drowsiness in 24 hours will be recorded |
Countries
Saudi Arabia
Contacts
Primary ContactAnwar ul huda, FRCA
Outcome results
None listed